<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04256473</url>
  </required_header>
  <id_info>
    <org_study_id>DUMAS-1.1</org_study_id>
    <nct_id>NCT04256473</nct_id>
  </id_info>
  <brief_title>Dual Thrombolytic Therapy With Mutant Pro-urokinase and Low Dose Alteplase for Ischemic Stroke</brief_title>
  <acronym>DUMAS</acronym>
  <official_title>Dual Thrombolytic Therapy With Mutant Pro-urokinase (M-pro-urokinase, HisproUK) and Low Dose Alteplase for Ischemic Stroke</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Erasmus Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>DUMAS is sponsored by an unrestricted grant from Thrombolytic Science International, paid to the institution.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Erasmus Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Randomized controlled phase II trial to test the safety and preliminary efficacy of a dual
      thrombolytic treatment consisting of a small intravenous (IV) bolus of alteplase followed by
      IV infusion of mutant pro-urokinase against usual treatment with IV alteplase in patients
      presenting with ischemic stroke.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 10, 2019</start_date>
  <completion_date type="Anticipated">March 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">February 1, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Any intracranial hemorrhage according to the Heidelberg Bleeding Classification on MRI</measure>
    <time_frame>24-48 hours post-treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Score on the National Institutes of Health Stroke Scale (NIHSS)</measure>
    <time_frame>at 24 hours and 5-7 days post-treatment</time_frame>
    <description>The NIHSS measures neurological deficit, ranging from 0 to 42, with higher scores indicating more severe neurological deficit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Score on the modified Rankin Scale (mRS)</measure>
    <time_frame>at 30 days</time_frame>
    <description>The mRS is an ordinal scale ranging from 0 (no symptoms) to 6 (death) measuring the degree of disability or dependence in everyday life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Infarct volume on MRI</measure>
    <time_frame>at 24-48 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change (pre-treatment vs. post-treatment) in abnormal perfusion volume based on TTP/MTT maps measured with CT perfusion at baseline and MRI</measure>
    <time_frame>at 24-48 hours post treatment.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary blood biomarkers of thrombolysis: d-dimer levels and fibrinogen levels.</measure>
    <time_frame>1 hour post-treatment, after 3 hours, and after 24 hours post-treatment,</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptomatic intracranial hemorrhage (sICH) according to the Heidelberg Bleeding Classification</measure>
    <time_frame>within 30 days</time_frame>
    <description>sICH is defined as any intracranial hemorrhage followed by a neurological deterioration that can be attributed to that hemorrhage, defined as an increase of &gt;= 4 points on the NIHSS or &gt;= 2 points on a specific NIHSS item.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death from any cause</measure>
    <time_frame>Within 30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major extracranial hemorrhage according to the ISTH criteria</measure>
    <time_frame>within 24 hours of study drug administration</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Ischemic Stroke</condition>
  <arm_group>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bolus of IV alteplase (5 mg) followed by continuous infusion of HisproUK 40 mg/hr during 60 minutes.
Depending on results of interim analyses, the alternate dose may be revised to a lower dose (30mg/hr during 60 minutes) or a higher dose (50mg/hr during 60 minutes).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Usual care with alteplase 0.9 mg/kg in 60 minutes</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mutant pro-urokinase</intervention_name>
    <description>Intravenous administration</description>
    <arm_group_label>Intervention</arm_group_label>
    <other_name>HisproUK</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alteplase</intervention_name>
    <description>Intravenous administration</description>
    <arm_group_label>Control</arm_group_label>
    <other_name>Actilyse</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  A clinical diagnosis of ischemic stroke;

          -  A score of at least 1 on the NIH Stroke Scale;

          -  CT ruling out intracranial hemorrhage;

          -  Treatment possible within 4.5 hours from symptom onset or last seen well;

          -  Meet the criteria for standard treatment for IV alteplase according to national
             guidelines27;

          -  Age of 18 years or older;

          -  Written informed consent (deferred).

        Exclusion Criteria:

          -  Candidate for endovascular thrombectomy (i.e., a proximal intracranial large artery
             occlusion on CTA);

          -  Contra-indication for treatment with IV alteplase according to national guidelines27:

               -  Arterial blood pressure exceeding 185/110 mmHg and not responding to treatment

               -  Blood glucose less than 2.7 or over 22.2 mmol/L

               -  Cerebral infarction in the previous 6 weeks with residual neurological deficit or
                  signs of recent infarction on neuro-imaging

               -  Head trauma in the previous 4 weeks

               -  Major surgery or serious trauma in the previous 2 weeks

               -  Gastrointestinal or urinary tract hemorrhage in the previous 2 weeks

               -  Previous intracerebral hemorrhage

               -  Use of anticoagulant with INR exceeding 1.7 or APTT exceeding 50 seconds

               -  Known thrombocyte count less than 90 x 109 /L

               -  Treatment with direct thrombin or factor X inhibitors, unless specific antidotum
                  has been given, i.e. idarucizumab in case of dabigatran use.

          -  Pre-stroke disability which interferes with the assessment of functional outcome at 90
             days, i.e. mRS &gt; 2;

          -  Known pregnancy or if pregnancy cannot be excluded, i.e. did not have intercourse for
             &gt; 6 months and no clinical signs of pregnancy, adequate use of any contraceptive
             method (e.g. intrauterine devices) or sterilization of the subject herself.

          -  Contra-indication for an MRI scan, i.e.:

               -  an MRI incompatible pacemaker, ICD, pacing wires and loop records

               -  metallic foreign bodies (e.g. intra-ocular)

               -  prosthetic heart valves

               -  blood vessel clips, coils or stents

               -  an implanted electronic and/or magnetic implant or pump (e.g. neurostimulator)

               -  cochlear implants

               -  mechanical implants (implanted less than 6 weeks ago)

               -  a copper intrauterine device

          -  Current Participation in any medical or surgical therapeutic trial other than DUMAS.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>DUMAS trial office</name>
      <address>
        <city>Rotterdam</city>
        <zip>3000 CA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>DUMAS trial office</last_name>
      <phone>0639583967</phone>
      <phone_ext>0639583967</phone_ext>
      <email>dumas@erasmusmc.nl</email>
    </contact>
    <investigator>
      <last_name>Diederik WJ Dippel, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <link>
    <url>https://dumas-trial.nl/</url>
    <description>DUMAS website</description>
  </link>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>February 3, 2020</study_first_submitted>
  <study_first_submitted_qc>February 4, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 5, 2020</study_first_posted>
  <last_update_submitted>April 3, 2020</last_update_submitted>
  <last_update_submitted_qc>April 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Erasmus Medical Center</investigator_affiliation>
    <investigator_full_name>Nadinda van der Ende</investigator_full_name>
    <investigator_title>PI: Prof. Dr. DWJ Dippel and A. van der Lugt</investigator_title>
  </responsible_party>
  <keyword>Randomized Controlled Trial</keyword>
  <keyword>Thrombolytic treatment</keyword>
  <keyword>Intracranial hemorrhage</keyword>
  <keyword>Mutant pro-urokinase</keyword>
  <keyword>Ischemic stroke</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Cerebral Infarction</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tissue Plasminogen Activator</mesh_term>
    <mesh_term>Saruplase</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

